Allogeneic CART-NKG2D cells therapy(Instituto De Investigación Hospital Universitario La Paz)

N/A

Report date: 2024/12/02 20:00:42

Base Information

Drug NameAllogeneic CART-NKG2D cells therapy(Instituto De Investigación Hospital Universitario La Paz)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstituto De Investigación Hospital Universitario La Paz

China Registration ClassN/A

Develop Information

Active CompaniesInstituto De Investigación Hospital Universitario La Paz

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A